Noramco completed the acquisition of the drug product business unit from Cambrex.

Noramco, a global active pharmaceutical ingredients manufacturer, completed the acquisition of the drug product business unit from Cambrex, a global contract development and manufacturing organization. Financial terms were not disclosed. “This acquisition allows Noramco to provide our customers with more sourcing options beyond APIs. With these additional capabilities, Noramco/Purisys customers can develop drug product formulations for their APIs for both clinical and commercial purposes. Having previously operated the Halo Pharmaceuticals business, I have a direct appreciation of the capabilities of both sites and look forward to working with existing and future customers while welcoming the almost 400 new employees to the Noramco group of companies,” Lee Karras, Noramco CEO.